Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

2020/05/22 by Feng-Cai Zhu, Fengcai Zhu, Yu-Hua Li +23 · 6 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #COVID-19 Clinical Research Studies #SARS-CoV-2 and COVID-19 Research #Virus-based gene therapy research

paper · pdf · doi:10.1016/s0140-6736(20)31208-3

openalex publication_date 2020/05/22 · crossref created 2020/05/22 · crossref issued 2020/06/01 · crossref published 2020/06/01 · crossref published-print 2020/06/01 · crossref deposited 2025/09/26 · openalex created_date 2025/10/10 · crossref indexed 2026/07/10 · openalex updated_date 2026/07/29

Cited by

• Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
• Vaccines for COVID-19
• Narrative Messages, Information Seeking and COVID-19 Vaccine Intention: The Moderating Role of Perceived Behavioral Control
• Characteristics of SARS-CoV-2 and COVID-19
• Viral vector platforms within the gene therapy landscape
• An mRNA Vaccine against SARS-CoV-2 — Preliminary Report